SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today it will present at the Jefferies 2017 Healthcare Conference in New York City.
Wouter Latour, M.D., chief executive officer, will be presenting on Wednesday, June 7, 2017 at 11:30 a.m., Eastern Standard Time. The presentation will cover Vaxart’s proprietary oral vaccine platform and latest developments on its tablet vaccine candidates for infectious diseases and immuno-oncology indications. Samir Singh, senior vice president of Corporate Development & Strategy, will be attending the conference as well.
Vaxart will be hosting one-on-one investor meetings at the conference. Please contact Isabel Zakoscielny at Jefferies to schedule an investor meeting with the company.
About Vaxart
Vaxart is a clinical-stage company developing tablet vaccines based on its proprietary oral vaccine platform. Its lead development programs are oral tablet vaccines for seasonal influenza, norovirus, respiratory syncytial virus (RSV) and immuno-oncology indications. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration, and eliminate the risk of needle-stick injury and medical waste associated with injectable vaccines. For more information, please visit www.vaxart.com.